Christopher J Chow1, Waddah B Al-Refaie, Anasooya Abraham, Abraham Markin, Wei Zhong, David A Rothenberger, Mary R Kwaan, Elizabeth B Habermann. 1. 1 Department of Surgery, University of Minnesota, Minneapolis, Minnesota 2 Department of Surgery, Georgetown University Hospital and Lombardi Comprehensive Cancer, Washington, District of Columbia 3 Genentech, South San Francisco, California 4 Division of Health Care Policy and Research and Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, Minnesota.
Abstract
BACKGROUND: More than 50 million people reside in rural America. However, the impact of patient rurality on colon cancer care has been incompletely characterized, despite its known impact on screening. OBJECTIVE: Our study sought to examine the impact of patient rurality on quality and comprehensive colon cancer care. DESIGN: We constructed a retrospective cohort of 123,129 patients with stage 0 to IV colon cancer. Rural residence was established based on the patient medical service study area designated by the registry. SETTINGS: The study was conducted using the 1996-2008 California Cancer Registry. PATIENTS: All of the patients diagnosed between 1996 and 2008 with tumors located in the colon were eligible for inclusion in this study. MAIN OUTCOME MEASURES: Baseline characteristics were compared by rurality status. Multivariate regression models then were used to examine the impact of rurality on stage in the entire cohort, adequate lymphadenectomy in stage I to III disease, and receipt of chemotherapy for stage III disease. Proportional-hazards regression was used to examine the impact of rurality on cancer-specific survival. RESULTS: Of all of the patients diagnosed with colon cancer, 18,735 (15%) resided in rural areas. Our multivariate models demonstrate that rurality was associated with later stage of diagnosis, inadequate lymphadenectomy in stage I to III disease, and lower likelihood of receiving chemotherapy for stage III disease. In addition, rurality was associated with worse cancer-specific survival. LIMITATIONS: We could not account for socioeconomic status directly, although we used insurance status as a surrogate. Furthermore, we did not have access to treatment location or distance traveled. We also could not account for provider or hospital case volume, patient comorbidities, or complications. CONCLUSIONS: A significant portion of patients treated for colon cancer live in rural areas. Yet, rural residence is associated with modest differences in stage, adherence to quality measures, and survival. Future endeavors should help improve care to this vulnerable population (see video, Supplemental Digital Content 1, http://links.lww.com/DCR/A143).
BACKGROUND: More than 50 million people reside in rural America. However, the impact of patientrurality on colon cancer care has been incompletely characterized, despite its known impact on screening. OBJECTIVE: Our study sought to examine the impact of patient rurality on quality and comprehensive colon cancer care. DESIGN: We constructed a retrospective cohort of 123,129 patients with stage 0 to IV colon cancer. Rural residence was established based on the patient medical service study area designated by the registry. SETTINGS: The study was conducted using the 1996-2008 California Cancer Registry. PATIENTS: All of the patients diagnosed between 1996 and 2008 with tumors located in the colon were eligible for inclusion in this study. MAIN OUTCOME MEASURES: Baseline characteristics were compared by rurality status. Multivariate regression models then were used to examine the impact of rurality on stage in the entire cohort, adequate lymphadenectomy in stage I to III disease, and receipt of chemotherapy for stage III disease. Proportional-hazards regression was used to examine the impact of rurality on cancer-specific survival. RESULTS: Of all of the patients diagnosed with colon cancer, 18,735 (15%) resided in rural areas. Our multivariate models demonstrate that rurality was associated with later stage of diagnosis, inadequate lymphadenectomy in stage I to III disease, and lower likelihood of receiving chemotherapy for stage III disease. In addition, rurality was associated with worse cancer-specific survival. LIMITATIONS: We could not account for socioeconomic status directly, although we used insurance status as a surrogate. Furthermore, we did not have access to treatment location or distance traveled. We also could not account for provider or hospital case volume, patient comorbidities, or complications. CONCLUSIONS: A significant portion of patients treated for colon cancer live in rural areas. Yet, rural residence is associated with modest differences in stage, adherence to quality measures, and survival. Future endeavors should help improve care to this vulnerable population (see video, Supplemental Digital Content 1, http://links.lww.com/DCR/A143).
Authors: Eugene J Lengerich; Thomas C Tucker; Raymond K Powell; Pat Colsher; Erik Lehman; Ann J Ward; Jennifer C Siedlecki; Stephen W Wyatt Journal: J Rural Health Date: 2005 Impact factor: 4.333
Authors: John Z Ayanian; Alan M Zaslavsky; Charles S Fuchs; Edward Guadagnoli; Cynthia M Creech; Rosemary D Cress; Lilia C O'Connor; Dee W West; Mark E Allen; Robert E Wolf; William E Wright Journal: J Clin Oncol Date: 2003-04-01 Impact factor: 44.544
Authors: Sharon A Dobie; Laura-Mae Baldwin; Jason A Dominitz; Barbara Matthews; Kevin Billingsley; William Barlow Journal: J Natl Cancer Inst Date: 2006-05-03 Impact factor: 13.506
Authors: Jessica B O'Connell; Melinda A Maggard; Jerome H Liu; David A Etzioni; Edward H Livingston; Clifford Y Ko Journal: World J Surg Date: 2004-06 Impact factor: 3.352
Authors: Sarah L Blair; Georgia R Sadler; Rebecca Bristol; Courtney Summers; Zanera Tahar; Sidney L Saltzstein Journal: BMC Public Health Date: 2006-07-26 Impact factor: 3.295
Authors: Whitney E Zahnd; Aimee S James; Wiley D Jenkins; Sonya R Izadi; Amanda J Fogleman; David E Steward; Graham A Colditz; Laurent Brard Journal: Cancer Epidemiol Biomarkers Prev Date: 2017-07-27 Impact factor: 4.254
Authors: Whitney E Zahnd; Katherine S Hyon; Paula Diaz-Sylvester; Sonya R Izadi; Graham A Colditz; Laurent Brard Journal: Cancer Causes Control Date: 2017-12-27 Impact factor: 2.506
Authors: Manila Jindal; Chaoyi Zheng; Humair S Quadri; Chukwuemeka U Ihemelandu; Young K Hong; Andrew K Smith; Vikas Dudeja; Nawar M Shara; Lynt B Johnson; Waddah B Al-Refaie Journal: J Am Coll Surg Date: 2017-04-14 Impact factor: 6.113
Authors: S Hong; L Rybicki; D M Abounader; B J Bolwell; R Dean; A T Gerds; B K Hamilton; B T Hill; D Jagadeesh; M Kalaycio; H D Liu; B Pohlman; R Sobecks; N S Majhail Journal: Bone Marrow Transplant Date: 2016-04-25 Impact factor: 5.483
Authors: Danielle Riley; Elizabeth A Chrischilles; Ingrid M Lizarraga; Mary Charlton; Brian J Smith; Charles F Lynch Journal: Breast Cancer Res Treat Date: 2022-01-24 Impact factor: 4.872